ArticleJournal of medicinal chemistry2022

Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells.

Xufen Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.